Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism

Brain Research Bulletin

Volumn 71, Issue 5, 2007, Pages 501-507

  Megyeri, Katalin ^a   Marko, Bernadett ^a   Sziray, Nora ^a   Gacsalyi, Istvan ^a   Juranyi, Zsolt ^a   Levay, Gyorgy ^a   Harsing Jr , Laszlo G ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

6 OHDA lesioned striatum; AMPA antagonists; Dopaminergic neurotransmission; GABAergic projection neurons; Levodopa; Parkinson's disease

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; CARBIDOPA; EGIS 8998; GYKI 53405; LEVODOPA; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE METABOLISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; MALE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; TURNOVER TIME;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; BENZODIAZEPINES; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; HOMOVANILLIC ACID; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA;

EID: 33846447144     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2006.11.003     Document Type: Article

References (58)

1. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 523 (1990) 36-44
2. Abraham G., Solyom S., Csuzdi E., Berzsenyi P., Ling I., Tarnawa I., Hamori T., Pallagi I., Horvath K., Andrasi F., Kapus G., Harsing Jr. L.G., Kiraly I., Patthy M., and Horvath G. New non competitive AMPA antagonists. Bioorg. Med. Chem. Lett. 8 (2000) 2127-2143
3. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorder. Trends Neurosci. 12 (1989) 366-375
4. Alexander T., Sortwell C.E., Sladek C.D., Roth R.H., and Steece-Collier K. Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures drived from Fisher 344 and Sprague-Dawley donors. Cell Transplant. 6 (1997) 309-315
5. Andrasi F. Talampanel. Drugs Future 26 (2001) 754-756
6. Beckstead R.M. N-methyl-d-aspartate acutely increases proenkephalin mRNA in the rat striatum. Synapse 21 (1995) 342-347
7. Bergman H., Wichmann T., and DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990) 1436-1438
8. Bolam J.P., Hanley J.J., Booth P.A.C., and Bevan M.D. Synaptic organization of the basal ganglia. J. Anat. 196 (2000) 527-542
9. Brotchie J.M., Michell I.J., Sambrook M.A., and Crossman A.R. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6 (1991) 133-138
10. Chase T.N., Oh J.D., and Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247 Suppl. 2 (2000) II36-II42
11. Chesselet M.-F., and Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19 (1996) 417-421
12. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of Parkinsonism-chronic treatment with l-DOPA. New Eng. J. Med. 280 (1969) 337-345
13. Duvoisin R.C. Variations in the "on-off" phenomenon. Adv. Neurol. 5 (1974) 339-340
14. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32 (1992) 804-812
15. Freund T.F., Powel J.F., and Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13 (1984) 1189-1215
16. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
17. Gossel M., Schmidt W.J., Loscher W., Zajaczkowski W., and Danysz W. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine depleted rats. J. Neural. Transm. 10 (1995) 27-39
18. Harsing Jr. L.G., and Zigmond M.J. Dopaminergic inhibition of striatal GABA release after 6-hydroxydopamine. Brain Res. 738 (1996) 142-145
19. Harsing Jr. L.G., and Zigmond M.J. Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 77 (1997) 419-429
20. 3H]GABA release in rat striatum. Neurochem. Int. 37 (2000) 33-45
21. Hefti F., Melamed E., and Wurtman R.J. Partial lesions of the nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195 (1980) 123-137
22. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45 (1987) 19-34
23. 3H]Dopamine release in rat striatum evoked by electric field stimulation of cortex in complex corticostriatal slice preparation in vitro. J. Neurosci. Methods 126 (2003) 57-67
24. Juranyi Z., Sziray N., Marko B., Levay G., and Harsing Jr. L.G. AMPA receptor blockade potentiates the stimulatory effect of l-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation. Crit. Rev. Neurobiol. 16 (2004) 129-139
25. Kemel M.L., Desban M., Glowinski J., and Gauchy C. Functional heterogeneity of the matrix compartment in the cat caudate nucleus as demonstrated by the cholinergic presynaptic regulation of dopamine release. Neuroscience 50 (1992) 597-610
26. Klockgether T., Turski L., Honore T., Zhang Z., Gash D.M., Kurlan R., and Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30 (1991) 717-723
27. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., and Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 (2000) 1589-1595
28. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44 (1994) 163-196
29. Leu W., Jiao Y.J., DelMar N., and Reiner A. Evidence for differential cortical input to direct versus indirect pathway striatal projection neurons in rats. J. Neurosci. 24 (2004) 8289-8299
30. Lloyd K.G., Davidson L., and Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of l-DOPA therapy. J. Pharm. Exp. Ther. 195 (1975) 453-464
31. Loschmann P.A., Lamge K.W., and Kunow M. Synergism of the AMPA-antagonist NBQX and NMDA-antagonist CPP with l-DOPA in models of Parkinson's disease. J. Neural. Transm. 3 (1991) 203-213
32. 2 agonists in a rat model of Parkinson's disease. Synapse 26 (1997) 381-391
33. Marin C., Jimenez A., Bonastre M., Vila M., Agid Y., Hirsch E.C., and Tolosa E. LY293558, an AMPA glutamate receptor antagonists, prevents and reverse levodopa-induced motor alterations in Parkinsonian rats. Synapse 42 (2001) 40-47
34. Marsden C.D., and Parkes J.D. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 7954 (1976) 292-296
35. Maruyama W., Naoi M., and Narabayashi H. The metabolism of l-DOPA and l-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the inraventricular fluid from parkinsonian patients. J. Neurol. Sci. 139 (1996) 141-148
36. Melamed E., Hefti G., Bitton V., and Globus M. Suppression of l-DOPA-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of l-DOPA in Parkinsonism. Neurology 34 (1984) 1566-1570
37. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., and Crossman A.R. Neural mechanism underlying parkinsonian symptoms based upon reginal uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32 (1989) 213-226
38. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., Vandergriff J.L., Baumbarger P., Siuda E., Gates M., Ogden A.M., Skolnick P., Zimmerman D.M., Niesenbaum E.S., Bleakman D., and O'Neill M.J. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharm. Exp. Ther. 306 (2003) 752-762
39. Ogawa N., Tanaka K., and Asanuma M. Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem. Res. 25 (2000) 755-758
40. Parent A., Levesque M., and Parent M. A re-evaluation of the current model of the basal ganglia. Parkinsonism Relat. Disord. 7 (2001) 193-198
41. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. fourth ed. (1998), Academic Press, New York
42. Perier C., Marin C., Bonastre M., Tolosa E., and Hirsch E.C. AMPA receptor agonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with l-dopa. Eur. J. Neurosci. 16 (2002) 2236-2240
43. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., and Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-dopa-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
44. Rinne U.K. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol. Scand. Suppl. 95 (1983) 19-26
45. Robertson H.A. Dopamine receptor interactions: some implication for the treatment of Parkinson's disease. Trends Neurosci. 15 (1992) 201-205
46. Schoenfeld R.I., and Uretsky N.J. Enhancement by 6-hydroxydopamine of the effects of DOPA upon the motor activity of rats. J. Pharm. Exp. Ther. 186 (1973) 616-624
47. Smith A.D., and Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13 (1990) 259-265
48. Snyder A.M., Keller R.W., and Zigmond M.J. Dopamin efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J. Pharm. Exp. Ther. 253 (1990) 867-876
49. Snyder A.M., Stricker E.M., and Zigmond M.J. Stress-induced neurological impairments in animal model of parkinsonism. Ann. Neurol. 18 (1985) 544-551
50. Starr M.N.S., Starr B.S., and Kuar S. Stimulation of basal and l-DOPA-induced motoractivity by glutamate antagonists in animal models of Parkinson's disease. Neurosci. Biobehav. Rev. 21 (1997) 437-446
51. 3H]GYKI-53405 to Xenopus brain membranes. Neuroreport 5 (1993) 93-94
52. Szenasi G., and Harsing Jr. L.G. Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors. Drug Discov. Today: Therap. Strategies 1 (2004) 69-76
53. Tarnawa I., and Vizi E.S. 2.3-Benzodiazepine AMPA antagonists. Restorative Neurol. Neurosci. 13 (1998) 41-57
54. Tarnawa I., Molnar P., Gal L., and Andrasi F. Inhibition of hippocampal field potentials by GYKI-52466 in vitro and in vivo. Acta Physiol. Hung. 79 (1992) 163-169
55. Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Vozari R., Agid Y., Tolosa E., and Hirsch E.C. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J. Neurochem. 73 (1999) 344-352
56. Wachtel H., Kunow M., and Loschmann P.A. NBQX and CPP potential dopamine agonist induced in substantia nigra lesioned rats. Neurosci. Lett. 142 (1992) 179-182
57. Zigmond M.J. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13 (1990) 290-296
58. Zigmond M.J. Chemical transmission in the brain: homeostatic regulationand its functional implications. In: Bloom F. (Ed). Progress in Brain Research (1994), Elsevier Science B.V. 115-122